Pavmed Inc. (NSDQ:PAVM) plans to drop the 510(k) application for its PortIO intraosseous infusion system and instead pursue a de novo pathway for its device, according to a document the company filed with the SEC yesterday.
The move is based on a recommendation from the FDA, the company said.
Get the full story at our sister site, Drug Delivery Business News.